Pulmonary blastomycosis following eculizumab therapy in a lung transplant recipient

Takashi Hirama, Rex Michael Santiago, Rohan John, Cecilia Chaparro

研究成果: Article査読

抄録

Objectives: Lung transplant recipients are at risk of developing many kinds of lung infection, such as community-acquired, nosocomial, opportunistic, and endemic. Here, we report a young lung transplant recipient who developed blastomycosis, which had most likely occurred following eculizumab treatment for atypical hemolytic uremia syndrome. We hypothesize that the agent interfering with C5 would influence the immune response against Blastomyces species. Although eculizumab has opened a new era for treatment of atypical hemolytic uremia syndrome and has led to the understanding that complementmediated pathology is needed, the risk of potentially fatal infections by blocking the complement pathway has not been fully elucidated. Careful follow-up and frequent tests to look for infections are needed after using this monoclonal antibody.

本文言語English
ページ(範囲)410-413
ページ数4
ジャーナルExperimental and Clinical Transplantation
18
3
DOI
出版ステータスPublished - 2020 6

ASJC Scopus subject areas

  • 移植

フィンガープリント

「Pulmonary blastomycosis following eculizumab therapy in a lung transplant recipient」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル